Global Opioid-induced Constipation Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report ID: GIR2112240134 | Category: Medical Care | Pages: 123 | Format: PDF | Published Date: July 12,2022

Request Sample Enquiry before buying Ask For Discount

Single User-$3480.00 Multi User-$5220.00

Report Description
View Table of Contents

Report Summary

The Opioid-induced Constipation market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Opioid-induced Constipation market size is estimated to be worth US$  million in 2021 and is forecast to a readjusted size of USD  million by 2028 with a CAGR of  % during review period. Drugstore accounting for  % of the Opioid-induced Constipation global market in 2021, is projected to value USD  million by 2028, growing at a  % CAGR in next six years. While Solid segment is altered to a  % CAGR between 2022 and 2028.
Global key companies of Opioid-induced Constipation include AstraZeneca, Takeda Pharmaceutical, Bausch Health, Abbott, and Bayer, etc. In terms of revenue, the global top four players hold a share over  % in 2021.
Market segmentation
Opioid-induced Constipation market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
    Solid
    Liquid
Market segment by Application, can be divided into
    Drugstore
    Hospital
    Others
Market segment by players, this report covers
    AstraZeneca
    Takeda Pharmaceutical
    Bausch Health
    Abbott
    Bayer
    Boehringer Ingelheim
    C.B. Fleet
    Cosmo Pharmaceuticals
    Daewoong
    Daiichi Sankyo
    GlaxoSmithKline
    Ironwood Pharmaceuticals
    Johnson and Johnson
    Merck
    Mundipharma
    Nektar Therapeutics
    Pfizer
    Progenics Pharmaceuticals
    Shionogi
    SLA Pharma
    Sucampo
    Synergy Pharmaceuticals
    Theravance
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Opioid-induced Constipation product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Opioid-induced Constipation, with revenue, gross margin and global market share of Opioid-induced Constipation from 2019 to 2022.
Chapter 3, the Opioid-induced Constipation competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Opioid-induced Constipation market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Opioid-induced Constipation research findings and conclusion, appendix and data source.

1 Market Overview
    1.1 Product Overview and Scope of Opioid-induced Constipation
    1.2 Classification of Opioid-induced Constipation by Type
        1.2.1 Overview: Global Opioid-induced Constipation Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Opioid-induced Constipation Revenue Market Share by Type in 2021
        1.2.3 Solid
        1.2.4 Liquid
    1.3 Global Opioid-induced Constipation Market by Application
        1.3.1 Overview: Global Opioid-induced Constipation Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Drugstore
        1.3.3 Hospital
        1.3.4 Others
    1.4 Global Opioid-induced Constipation Market Size & Forecast
    1.5 Global Opioid-induced Constipation Market Size and Forecast by Region
        1.5.1 Global Opioid-induced Constipation Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Opioid-induced Constipation Market Size by Region, (2017-2022)
        1.5.3 North America Opioid-induced Constipation Market Size and Prospect (2017-2028)
        1.5.4 Europe Opioid-induced Constipation Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Opioid-induced Constipation Market Size and Prospect (2017-2028)
        1.5.6 South America Opioid-induced Constipation Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Opioid-induced Constipation Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Opioid-induced Constipation Market Drivers
        1.6.2 Opioid-induced Constipation Market Restraints
        1.6.3 Opioid-induced Constipation Trends Analysis
2 Company Profiles
    2.1 AstraZeneca
        2.1.1 AstraZeneca Details
        2.1.2 AstraZeneca Major Business
        2.1.3 AstraZeneca Opioid-induced Constipation Product and Solutions
        2.1.4 AstraZeneca Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 AstraZeneca Recent Developments and Future Plans
    2.2 Takeda Pharmaceutical
        2.2.1 Takeda Pharmaceutical Details
        2.2.2 Takeda Pharmaceutical Major Business
        2.2.3 Takeda Pharmaceutical Opioid-induced Constipation Product and Solutions
        2.2.4 Takeda Pharmaceutical Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Takeda Pharmaceutical Recent Developments and Future Plans
    2.3 Bausch Health
        2.3.1 Bausch Health Details
        2.3.2 Bausch Health Major Business
        2.3.3 Bausch Health Opioid-induced Constipation Product and Solutions
        2.3.4 Bausch Health Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Bausch Health Recent Developments and Future Plans
    2.4 Abbott
        2.4.1 Abbott Details
        2.4.2 Abbott Major Business
        2.4.3 Abbott Opioid-induced Constipation Product and Solutions
        2.4.4 Abbott Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Abbott Recent Developments and Future Plans
    2.5 Bayer
        2.5.1 Bayer Details
        2.5.2 Bayer Major Business
        2.5.3 Bayer Opioid-induced Constipation Product and Solutions
        2.5.4 Bayer Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Bayer Recent Developments and Future Plans
    2.6 Boehringer Ingelheim
        2.6.1 Boehringer Ingelheim Details
        2.6.2 Boehringer Ingelheim Major Business
        2.6.3 Boehringer Ingelheim Opioid-induced Constipation Product and Solutions
        2.6.4 Boehringer Ingelheim Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
    2.7 C.B. Fleet
        2.7.1 C.B. Fleet Details
        2.7.2 C.B. Fleet Major Business
        2.7.3 C.B. Fleet Opioid-induced Constipation Product and Solutions
        2.7.4 C.B. Fleet Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 C.B. Fleet Recent Developments and Future Plans
    2.8 Cosmo Pharmaceuticals
        2.8.1 Cosmo Pharmaceuticals Details
        2.8.2 Cosmo Pharmaceuticals Major Business
        2.8.3 Cosmo Pharmaceuticals Opioid-induced Constipation Product and Solutions
        2.8.4 Cosmo Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Cosmo Pharmaceuticals Recent Developments and Future Plans
    2.9 Daewoong
        2.9.1 Daewoong Details
        2.9.2 Daewoong Major Business
        2.9.3 Daewoong Opioid-induced Constipation Product and Solutions
        2.9.4 Daewoong Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Daewoong Recent Developments and Future Plans
    2.10 Daiichi Sankyo 
        2.10.1 Daiichi Sankyo Details
        2.10.2 Daiichi Sankyo Major Business
        2.10.3 Daiichi Sankyo Opioid-induced Constipation Product and Solutions
        2.10.4 Daiichi Sankyo Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Daiichi Sankyo Recent Developments and Future Plans
    2.11 GlaxoSmithKline
        2.11.1 GlaxoSmithKline Details
        2.11.2 GlaxoSmithKline Major Business
        2.11.3 GlaxoSmithKline Opioid-induced Constipation Product and Solutions
        2.11.4 GlaxoSmithKline Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 GlaxoSmithKline Recent Developments and Future Plans
    2.12 Ironwood Pharmaceuticals
        2.12.1 Ironwood Pharmaceuticals Details
        2.12.2 Ironwood Pharmaceuticals Major Business
        2.12.3 Ironwood Pharmaceuticals Opioid-induced Constipation Product and Solutions
        2.12.4 Ironwood Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Ironwood Pharmaceuticals Recent Developments and Future Plans
    2.13 Johnson and Johnson
        2.13.1 Johnson and Johnson Details
        2.13.2 Johnson and Johnson Major Business
        2.13.3 Johnson and Johnson Opioid-induced Constipation Product and Solutions
        2.13.4 Johnson and Johnson Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.13.5 Johnson and Johnson Recent Developments and Future Plans
    2.14 Merck
        2.14.1 Merck Details
        2.14.2 Merck Major Business
        2.14.3 Merck Opioid-induced Constipation Product and Solutions
        2.14.4 Merck Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.14.5 Merck Recent Developments and Future Plans
    2.15 Mundipharma
        2.15.1 Mundipharma Details
        2.15.2 Mundipharma Major Business
        2.15.3 Mundipharma Opioid-induced Constipation Product and Solutions
        2.15.4 Mundipharma Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.15.5 Mundipharma Recent Developments and Future Plans
    2.16 Nektar Therapeutics
        2.16.1 Nektar Therapeutics Details
        2.16.2 Nektar Therapeutics Major Business
        2.16.3 Nektar Therapeutics Opioid-induced Constipation Product and Solutions
        2.16.4 Nektar Therapeutics Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.16.5 Nektar Therapeutics Recent Developments and Future Plans
    2.17 Pfizer
        2.17.1 Pfizer Details
        2.17.2 Pfizer Major Business
        2.17.3 Pfizer Opioid-induced Constipation Product and Solutions
        2.17.4 Pfizer Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.17.5 Pfizer Recent Developments and Future Plans
    2.18 Progenics Pharmaceuticals
        2.18.1 Progenics Pharmaceuticals Details
        2.18.2 Progenics Pharmaceuticals Major Business
        2.18.3 Progenics Pharmaceuticals Opioid-induced Constipation Product and Solutions
        2.18.4 Progenics Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.18.5 Progenics Pharmaceuticals Recent Developments and Future Plans
    2.19 Shionogi
        2.19.1 Shionogi Details
        2.19.2 Shionogi Major Business
        2.19.3 Shionogi Opioid-induced Constipation Product and Solutions
        2.19.4 Shionogi Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.19.5 Shionogi Recent Developments and Future Plans
    2.20 SLA Pharma
        2.20.1 SLA Pharma Details
        2.20.2 SLA Pharma Major Business
        2.20.3 SLA Pharma Opioid-induced Constipation Product and Solutions
        2.20.4 SLA Pharma Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.20.5 SLA Pharma Recent Developments and Future Plans
    2.21 Sucampo
        2.21.1 Sucampo Details
        2.21.2 Sucampo Major Business
        2.21.3 Sucampo Opioid-induced Constipation Product and Solutions
        2.21.4 Sucampo Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.21.5 Sucampo Recent Developments and Future Plans
    2.22 Synergy Pharmaceuticals
        2.22.1 Synergy Pharmaceuticals Details
        2.22.2 Synergy Pharmaceuticals Major Business
        2.22.3 Synergy Pharmaceuticals Opioid-induced Constipation Product and Solutions
        2.22.4 Synergy Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.22.5 Synergy Pharmaceuticals Recent Developments and Future Plans
    2.23 Theravance
        2.23.1 Theravance Details
        2.23.2 Theravance Major Business
        2.23.3 Theravance Opioid-induced Constipation Product and Solutions
        2.23.4 Theravance Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.23.5 Theravance Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Opioid-induced Constipation Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Opioid-induced Constipation Players Market Share in 2021
        3.2.2 Top 10 Opioid-induced Constipation Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Opioid-induced Constipation Players Head Office, Products and Services Provided
    3.4 Opioid-induced Constipation Mergers & Acquisitions
    3.5 Opioid-induced Constipation New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global Opioid-induced Constipation Revenue and Market Share by Type (2017-2022)
    4.2 Global Opioid-induced Constipation Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
    5.1 Global Opioid-induced Constipation Revenue Market Share by Application (2017-2022)
    5.2 Global Opioid-induced Constipation Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
    6.1 North America Opioid-induced Constipation Revenue by Type (2017-2028)
    6.2 North America Opioid-induced Constipation Revenue by Application (2017-2028)
    6.3 North America Opioid-induced Constipation Market Size by Country
        6.3.1 North America Opioid-induced Constipation Revenue by Country (2017-2028)
        6.3.2 United States Opioid-induced Constipation Market Size and Forecast (2017-2028)
        6.3.3 Canada Opioid-induced Constipation Market Size and Forecast (2017-2028)
        6.3.4 Mexico Opioid-induced Constipation Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
    7.1 Europe Opioid-induced Constipation Revenue by Type (2017-2028)
    7.2 Europe Opioid-induced Constipation Revenue by Application (2017-2028)
    7.3 Europe Opioid-induced Constipation Market Size by Country
        7.3.1 Europe Opioid-induced Constipation Revenue by Country (2017-2028)
        7.3.2 Germany Opioid-induced Constipation Market Size and Forecast (2017-2028)
        7.3.3 France Opioid-induced Constipation Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Opioid-induced Constipation Market Size and Forecast (2017-2028)
        7.3.5 Russia Opioid-induced Constipation Market Size and Forecast (2017-2028)
        7.3.6 Italy Opioid-induced Constipation Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Opioid-induced Constipation Revenue by Type (2017-2028)
    8.2 Asia-Pacific Opioid-induced Constipation Revenue by Application (2017-2028)
    8.3 Asia-Pacific Opioid-induced Constipation Market Size by Region
        8.3.1 Asia-Pacific Opioid-induced Constipation Revenue by Region (2017-2028)
        8.3.2 China Opioid-induced Constipation Market Size and Forecast (2017-2028)
        8.3.3 Japan Opioid-induced Constipation Market Size and Forecast (2017-2028)
        8.3.4 South Korea Opioid-induced Constipation Market Size and Forecast (2017-2028)
        8.3.5 India Opioid-induced Constipation Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Opioid-induced Constipation Market Size and Forecast (2017-2028)
        8.3.7 Australia Opioid-induced Constipation Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
    9.1 South America Opioid-induced Constipation Revenue by Type (2017-2028)
    9.2 South America Opioid-induced Constipation Revenue by Application (2017-2028)
    9.3 South America Opioid-induced Constipation Market Size by Country
        9.3.1 South America Opioid-induced Constipation Revenue by Country (2017-2028)
        9.3.2 Brazil Opioid-induced Constipation Market Size and Forecast (2017-2028)
        9.3.3 Argentina Opioid-induced Constipation Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Opioid-induced Constipation Revenue by Type (2017-2028)
    10.2 Middle East & Africa Opioid-induced Constipation Revenue by Application (2017-2028)
    10.3 Middle East & Africa Opioid-induced Constipation Market Size by Country
        10.3.1 Middle East & Africa Opioid-induced Constipation Revenue by Country (2017-2028)
        10.3.2 Turkey Opioid-induced Constipation Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Opioid-induced Constipation Market Size and Forecast (2017-2028)
        10.3.4 UAE Opioid-induced Constipation Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Opioid-induced Constipation Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?